Madrigal

Madrigal Pharmaceuticals (MDGL)

Company Description

Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis (NASH), diabetes, dyslipidemia and cardiovascular disease.

COMPANY ADDRESS
200 Barr Harbor Drive, Suite 400
West Conshohocken, PA 19428
United States

COMPANY EMAIL
info@madrigalpharma.com

COMPANY WEBSITE



Get BioInvest's perspective on Madrigal Pharmaceutical's CEO


Latest Company News

Drilling into the Technicals & Valuation For Madrigal Pharmaceuticals, Inc ... Stock Talker - 10 hours ago Madrigal Pharmaceuticals, Inc. (NasdaqCM:MDGL) boasts a Price to Book ratio of 5.294168. This ratio is calculated by dividing the current share price by the book value per share. [...]
Tue, Jun 27, 2017 11:48:00 AM, Continue reading at the source
Active Runner in Focus: Madrigal Pharmaceuticals Inc (MDGL) Union Trade Journal - Jun 26, 2017 Shares of Madrigal Pharmaceuticals Inc (MDGL) is moving on volatility today 3.34% or 0.50 rom the open. The NASDAQ listed company saw a recent bid of 15.49 on 7315 volume. [...]
Mon, Jun 26, 2017 5:52:00 PM, Continue reading at the source
Decision Time: Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Stock Technicals Hit ... CML News - Jun 23, 2017 Decision Time: Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) now sits in the perhaps the most difficult technical position -- the stock has no urgency in its direction and that has left it at an inflection point. [...]
Fri, Jun 23, 2017 3:00:00 AM, Continue reading at the source
Madrigal Pharmaceuticals Announces $35 Million Private Placement Offering GlobeNewswire (press release) - Jun 21, 2017 WEST CONSHOHOCKEN, Pa., June 21, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that it has entered into a definitive securities purchase agreement with a group of institutional accredited investors for ... The Head-To-Head Contrast: Aviragen Therapeutics (AVIR) & Madrigal ... - BangaloreWeekly [...]
Wed, Jun 21, 2017 12:56:00 PM, Continue reading at the source
Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results GlobeNewswire (press release) - May 11, 2017 CONSHOHOCKEN, Pa., May 11, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2017 financial results. [...]
Thu, May 11, 2017 9:00:00 PM, Continue reading at the source
Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License ... GlobeNewswire (press release) - Sep 19, 2016 CONSHOHOCKEN, Pa. and WATERTOWN, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) and Tarveda Therapeutics, Inc. today announced an exclusive worldwide license agreement providing for the ... With $163M Deal, Tarveda Revives Synta Pharma's Cancer Drug Work - Xconomy [...]
Mon, Sep 19, 2016 11:31:00 AM, Continue reading at the source
Synta - Madrigal Merger: Is There A Potential Value Play Here? Seeking Alpha - Aug 23, 2016 On April 13, 2016 Synta and Madrigal Pharmaceuticals (NASDAQ:MDGL) entered into an arrangement and plan of merger pursuant to which Saffron Merger Sub Inc., a wholly owned subsidiary of Synta, will merge into MDGL, with Madrigal surviving as the ... [...]
Tue, Aug 23, 2016 11:48:00 PM, Continue reading at the source
14.97 MarketWatch - Jul 25, 2016 Madrigal Pharmaceuticals Inc. Madrigal Pharmaceuticals, Inc. clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel compounds for the treatment of cardiovascular, metabolic and liver diseases. [...]
Mon, Jul 25, 2016 8:03:00 PM, Continue reading at the source
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading ... GlobeNewswire (press release) - Jul 22, 2016 FORT WASHINGTON, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the ... [...]
Fri, Jul 22, 2016 3:31:00 PM, Continue reading at the source
Synta Pharma and Madrigal Pharma to merge in all-stock deal Seeking Alpha - Apr 14, 2016 Madrigal shareholders will own 64% of the combined company while Synta shareholders will own 36%. The deal should close by the end of Q3. Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular ... - Business Wire (press release) Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals - Yahoo News [...]
Thu, Apr 14, 2016 11:26:00 AM, Continue reading at the source